Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.

Anti-cancer drugs - 1 Oct 2015

Sereno María, Moreno Victor, Moreno Rubio Juan, Gómez-Raposo César, García Sánchez Sagrario, Hernández Jusdado Rebeca, Falagan Sandra, Zambrana Tébar Francisco, Casado Sáenz Enrique

Abstract excerpt

Lung adenocarcinoma includes recurrent activating oncogenic mutations (EGFR, EML4-ALK, ROS1) that have been associated with response to EGFR and ALK inhibitors. Platinum-based chemotherapy is the standard therapy for non-oncodrivers population. Sorafenib is a small molecule that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2, VEGFR-3 and PDGFR approved for advanced renal cell and hepatocellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Niacinamide

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins B-raf

Share to Sorafenib

Source

Identifiers

PMID: 26237499
DOI: 10.1097/CAD.0000000000000277

Genes

ALK
BRAF
EGFR
EML4
KIT
RET
ROS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.PMID 26237499Read ↗

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.Semantic proximity Read ↗

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).Semantic proximity Read ↗

Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.Semantic proximity Read ↗

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.Semantic proximity Read ↗

A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.Semantic proximity Read ↗

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.Semantic proximity Read ↗

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].Semantic proximity Read ↗

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.Semantic proximity Read ↗

[A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib].Semantic proximity Read ↗

Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.Semantic proximity Read ↗

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.Semantic proximity Read ↗

[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.